BriaCell Therapeutics (BCT.TO), up 41% in U.S. pre-market trading, on Thursday confirmed the sustained complete resolution of the lung metastasis, first reported in February, two months after initial treatment.
The latest data at four months also demonstrates stable disease elsewhere, the company said.
The patient, a 78-year-old woman with metastatic breast cancer, had failed several prior lines of therapy and received the lowest dose level in the Phase 1/2a Bria-OTS study. At enrollment last November, she had extensive metastases including bone, lymph node and lung involvement. Following Bria-OTS injections every two weeks for six weeks, and subsequent dosing every three weeks, the lung metastasis completely resolved with stable disease elsewhere. This response is now confirmed and shows the potentially promising activity of the Bria-OTS platform as monotherapy, Briacell said.
"This unprecedented anti-cancer response in the first patient dosed with Bria-OTS is an important milestone for us and provides early validation of BriaCell's personalized immunotherapy approach," said Chief Executive Dr. William Williams.
The company's shares were last seen up US$2.30, to US$7.73, in New York trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。